Turner Syndrome Drug Market - Novartis AG, ALLERGAN, Bausch Health, Pfizer Inc., Johnson & Johnson Services, Inc., , Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Smiths Group plc, Abbott, Lupin Pharmaceuticals, Inc.,, GlaxoSmithKline plc, American Ge
Global Turner Syndrome Drug Market is rising gradually registering a substantial CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the increasing awareness and concerns regarding the women health, increasing prevalence of genetic disorders and high expenditure in healthcare sector and favorable government regulation.
Market Definition: Global Turner Syndrome Drug Market
Turner Syndrome is one of the rare chromosomal disorders, which is diagnosed only in the female population, it is also known as congenital ovarian hypoplasia syndrome. Turner syndrome occurs when one of the X chromosome is partially or completely missing in females. Affected female’s experiences a variety of symptoms like webbed neck, a low hairline at the neck’s back, lymphedema and short stature. Turner syndrome is quite variable that can differ from one person to another. Most of the affected females are infertile due to the premature ovarian failure. Additionally a variety of symptoms can also occur including abnormalities of the eyes and ears, skeletal malformations, heart problems and kidney disorders. Affected females generally have normal intelligence but may experience some learning disabilities. It can be diagnosed before birth or shortly after birth.
Request for FREE Sample Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-turner-syndrome-drug-market
In 2018, according to the report of National Institute of Health (NIH),US, , the classic karyotype was found only in 45% of patients and the remaining 55% had a mosaic karyotype, a karyotype with abnormality in X chromosome or may include Y chromosome or its fragments. A karyotype analysis of 67 patients with Turner syndrome in Suzhou, China, around 44.7 % had 45, X karyotype, 17.9% had mosaic karyotype, 31.4% had a chromosomal structural abnormality and 31.4% had karyotype with Y chromosome or its fragments. The prevalence rate of Turner syndrome is estimated at 1 in 2,500 female live births).
The increasing awareness and concerns regarding the women health is driving the market growth
Increasing prevalence of genetic disorders is increasing the market growth
Rising female population a factor driving the market growth
Increasing FDA approvals for the treatment of the diseases followed by growing biotechnology sector is elevating the market growth
High cost of annual treatment is hampering the market growth
Low per capita healthcare expenditure and lack of the awareness within the low and middle income countries is restraining the market growth
Large number of side effects of drugs such as headache, joint and muscle pain, edema, nausea and dizziness is hindering the market growth
Browse Full Report with Details TOC @ https://databridgemarketresearch.com/toc/?dbmr=global-turner-syndrome-drug-market
Segmentation: Global Turner Syndrome Drug Market
Classical Turner Syndrome
Mosaic Turner syndrome
By Drugs Type
By Therapy Type
Growth Hormone Therapy
Estrogen and Progesterone Replacement Therapy
By Routes of Administration
By End Users
Rest of South America
Rest of Europe
Rest of Asia-Pacific
Middle East & Africa
United Arab Emirates
Rest of Middle East & Africa
Key Developments in the Market
In Febraury 2018, GeneScience Pharmaceuticals Co., Ltd is developing PEG rhGH injection which is under phase 3 of clinical trials for the treatment of short stature due to turner syndrome, if it passes the clinical trials it will be the first patented drug for the treatment of turner syndrome.
In February 2017, Novo Nordisk A/S is developing Somatropin which is under Phase lll of clinical trial for the treatment of Turner syndrome. This drug will help in the treatment of short stature due to growth hormone deficiency in children’s.
Speak to Our Analyst for more Details:- https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-turner-syndrome-drug-market
Global turner syndrome drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global Turner syndrome drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Inquiry before Buying @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-turner-syndrome-drug-market
Key Market Players
Few of the major competitors currently working in the global turner syndrome drug are Novartis AG, ALLERGAN, Bausch Health, Pfizer Inc., Johnson & Johnson Services, Inc., , Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Smiths Group plc, Abbott, Lupin Pharmaceuticals, Inc.,, GlaxoSmithKline plc, American Gene Technologies, Inc, , Codexis, BioMarin, Ultragenyx Pharmaceutical, Rocket Medical plc., Novo Nordisk A/S, Sanofi, Medtronic, Sandoz International GmbH, Ipsen Pharma and few among others.
Data Bridge Market Research
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Turner Syndrome Drug Market - Novartis AG, ALLERGAN, Bausch Health, Pfizer Inc., Johnson & Johnson Services, Inc., , Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Smiths Group plc, Abbott, Lupin Pharmaceuticals, Inc.,, GlaxoSmithKline plc, American Ge here
News-ID: 1825280 • Views: 234
More Releases from Data Bridge Market Research
Europe Anti-Money Laundering Software Market | In-Depth Swot Analysis and Future …
Europe Anti-Money Laundering Software Market By Component (Software and Services), Product Type (Customer Identity Management Software, Transaction Monitoring Software, Currency Transaction Reporting Software, Compliance Management Software, and Others), Deployment Model (On-premise and Cloud), Organization Size (Large Organization and Small & Medium Organization), Application (Spend Analytics, Vendor Management, Contract Management, and Others), End-Market (Banking, Financial Services and Insurance, Retail, IT & Telecommunication, Government, Healthcare, Defense, Transport and Logistics, Energy & Utilities,
Global Passenger Information System Market | Key Players EUROTECH; DILAX Intelco …
Global Passenger Information System Market By Product (Hardware, Software, Services), Type (Passenger Information Display Systems, Passenger Information Announcement Systems, Emergency Communication Systems, Infotainment Systems, Passenger Information Mobile Application), Application (Railways, Roadways, Airways), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2026 Get a Copy of Sample Report Now! @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-passenger-information-system-market&kp Major Market Competitors/Players Few of the major competitors currently working in the global
Global Artificial Intelligence Market Analysis Data of Leading Players | Microso …
New Growth Forecast Report on Global Artificial Intelligence Market, By Offering (Hardware, Software and Services), By Technology (Machine Learning, Natural Language Processing and others), By Type (Artificial Neural Network, Digital Assistance System and others), By Application (Deep Learning, Smart Robots and others), By End-User Industry (Healthcare, Manufacturing and others) and By Geographical Segments- Industry Trends and Forecast to 2025 Analyzes current market size and upcoming 7 years growth of this
Data Center Accelerator Market Recent Study Including Growth Factors, Applicatio …
New Growth Forecast Report on Global Data Center Accelerator Market,By Processor Type (CPU, GPU, FPGA, ASIC), Type (HPC Accelerator, Cloud Accelerator), Application (Deep Learning Training, Public Cloud Interface, Enterprise Interface) Geographical Segments (North America, South America, Europe, Asia-Pacific, Middle East and Africa)- Industry Trends and Forecast to 2025 Analyzes current market size and upcoming 7 years growth of this industry Data Center Accelerator market report is a comprehensive study on how
More Releases for Turner
Davies Turner Air Cargo receives AEO certificate
Davies Turner Air Cargo has been officially presented with its Authorised Economic Operator (AEO) certificate by HM Revenue & Customs. The airfreight forwarder recently became the one of the first AEOs in Europe. Attached is a photo taken at a recent official presentation ceremony which took place at HM Treasury. It shows left to right: Denham Baxter (Managing Director - Davies Turner Air Cargo); Peter Castree (Chairman - Davies Turner
DAVIES TURNER IRELAND STRENGTHENS SENIOR MANAGEMENT
The Davies Turner Group has strengthened the senior management of its subsidiary in Ireland with the appointment of Ciaran Delmar and John Culligan as Joint Managing Directors of Davies Turner Ireland Ltd. Both have joined from senior roles with Expeditors Ireland. Philip Stephenson, Joint Managing Director of the Davies Turner Group, says: “These appointments show our customers and the market that we are serious in our ambitions to further enhance
DAVIES TURNER AIR CARGO FIRST WITH FULL AEO STATUS
Effective April 5th 2008, Davies Turner Air Cargo will become one of Europe’s first Authorised Economic Operators (AEOs). The freight forwarder and logistics services provider has been advised by UK accreditation authority, HM Revenue & Customs that its AEO application has been successful and it has achieved full certification (Type F) which entitles the company to benefits under security and safety, as well as customs simplifications (effective July 1st 2009). The AEO
Connecticut Construction Workers Protest Against Turner Construction
(Hartford, Connecticut) – Over 50 Connecticut construction workers are scheduled to participate in an informational protest in front of Saint Francis Hospital, Woodland Street, Hartford, CT on Tuesday, January 29, 2008 from 8 a.m. to 11 a.m. Members of the Connecticut Laborers’ District Council are expanding their protest of Turner Construction Company's, Milford, CT, hiring and community standards policies. Last week, Connecticut Laborers’ District Council leader Charles LeConche requested
DAVIES TURNER CHANNELS INVESTMENT INTO BRISTOL
Independent freight forwarder, Davies Turner - daviesturner.co.uk - has started to build a multi-million pound expansion to its existing freight and logistics hub in Bristol. The overall warehouse area at Avonmouth will be tripled in size to give an overall footprint of 10,500 sq. metres. The construction work comes just over a decade after Davies Turner opened its Phase 1 transit hub for the West Country at a cost then of £2
DAVIES TURNER BAGS BRACE OF INDUSTRY AWARDS
Davies Turner has again been voted ‘Freight Forwarder of the Year’ in a nationwide shipping industry poll conducted by Informa, the leading international provider of specialist information and services for various business communities. In winning the trophy, which was voted for by readers of Informa’s flagship export directory, Lloyd’s Loading List, Davies Turner saw off competition from two multinationals that had also made the final shortlist. Comments Joint Managing Director, Philip Stephenson: